AbbVie End Period Cash Flow from 2010 to 2025

ABBV Stock  USD 192.97  1.22  0.64%   
AbbVie End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 9.8 B in 2025. During the period from 2010 to 2025, AbbVie End Period Cash Flow regression line of quarterly data had mean square error of 70049684.8 T and geometric mean of  3,114,588,680. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
13.1 B
Current Value
7.3 B
Quarterly Volatility
7.3 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.5 B, Interest Expense of 2.7 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of AbbVie Inc over the last few years. It is AbbVie's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

AbbVie End Period Cash Flow Regression Statistics

Arithmetic Mean9,916,693,566
Geometric Mean3,114,588,680
Coefficient Of Variation89.53
Mean Deviation4,715,502,413
Median9,201,000,000
Standard Deviation8,878,339,663
Sample Variance78824915.2T
Range39.9B
R-Value0.41
Mean Square Error70049684.8T
R-Squared0.17
Significance0.11
Slope770,175,956
Total Sum of Squares1182373727.6T

AbbVie End Period Cash Flow History

20259.8 B
202414.7 B
202312.8 B
20229.2 B
20219.7 B
20208.4 B
201939.9 B

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow14.7 B9.8 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.